Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: a prognosis study

Supplemental Digital Content is available in the text Aims Chronic kidney dysfunction (CKD) and persistent congestion influence heart failure prognosis, but little is known about the role of inflammation in this association. We assessed the relationship between inflammatory biomarkers, persistent congestion and CKD and their prognostic implications in patients with acute heart failure. Methods We enrolled 97 hospitalised patients (mean age: 66 ± 12 years, ejection fraction: 30 ± 8%) with acute heart failure. Before discharge, congestion was assessed using a heart failure scoring system on the basis of Framingham criteria. Circulating levels of high-sensitivity C-reactive protein, TGF-β-1, IL-1, IL-6, IL-10, TNF-α, soluble tumour necrosis factor receptor type 1 and 2 were measured. Patients were divided into four groups according to the presence of CKD (estimated glomerular filtration rate <60 ml/min/1.73 m2) and congestion (Framingham heart failure score ≥2). The primary end point was the combination of death and rehospitalisation for acute heart failure. Results During a median follow-up of 32 months, 37 patients died and 14 were rehospitalised for acute heart failure. Patients with CKD and congestion had significantly higher TNF-α (P = 0.037), soluble tumour necrosis factor receptor type 1 (P = 0.0042) and soluble tumour necrosis factor receptor type 2 (P = 0.001), lower TGF-β-1 (P = 0.02) levels, and the worst outcome (P < 0.0001). Congestion (P = 0.01) and CKD (P = 0.02) were independent predictors of the end-point together with N-terminal prohormone of brain natriuretic peptide (P = 0.002) and TNF-α (P = 0.004). TNF-α attenuated the direct relation between CKD, congestion and outcome, explaining 40% of the difference in the outcome. Conclusion In patients hospitalised with acute heart failure, the prognostic impact of persistent congestion and CKD is associated with increased cytokine levels, which may also interfere with the outcome.

[1]  A. Natali,et al.  Haemodynamic and metabolic phenotyping of hypertensive patients with and without heart failure by combining cardiopulmonary and echocardiographic stress test , 2020, European journal of heart failure.

[2]  S. Solomon,et al.  Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. , 2019, JACC. Heart failure.

[3]  S. Taddei,et al.  The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure , 2019, Heart Failure Reviews.

[4]  A. Natali,et al.  Value of combined cardiopulmonary and echocardiography stress test to characterize the haemodynamic and metabolic responses of patients with heart failure and mid-range ejection fraction. , 2019, European heart journal cardiovascular Imaging.

[5]  J. McMurray,et al.  Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure , 2019, European journal of heart failure.

[6]  R. Pedrinelli,et al.  The Added Value of Exercise Stress Echocardiography in Patients With Heart Failure. , 2019, The American journal of cardiology.

[7]  E. Picano,et al.  Lung Ultrasound for the Cardiologist. , 2018, JACC. Cardiovascular imaging.

[8]  C. Ronco,et al.  Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1 , 2018, Cardiorenal Medicine.

[9]  P. Ponikowski,et al.  Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. , 2018, International journal of cardiology.

[10]  O. Smiseth,et al.  Mean Right Atrial Pressure for Estimation of Left Ventricular Filling Pressure in Patients with Normal Left Ventricular Ejection Fraction: Invasive and Noninvasive Validation , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[11]  Akshay S. Desai,et al.  Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study , 2017, European journal of heart failure.

[12]  Z. Abassi,et al.  Involvement of Cytokines in the Pathogenesis of Salt and Water Imbalance in Congestive Heart Failure , 2017, Front. Immunol..

[13]  P. Heidenreich.  Inflammation and Heart Failure: Therapeutic or Diagnostic Opportunity? , 2017, Journal of the American College of Cardiology.

[14]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.

[15]  S. Epelman,et al.  Chronic Heart Failure and Inflammation: What Do We Really Know? , 2016, Circulation research.

[16]  T. Ueland,et al.  Inflammatory cytokines as biomarkers in heart failure. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[17]  D. Mann.  Innate immunity and the failing heart: the cytokine hypothesis revisited. , 2015, Circulation research.

[18]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[19]  Laura G. Qualls,et al.  In‐Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization , 2014, Journal of the American Heart Association.

[20]  J. McMurray,et al.  Inflammatory cytokines in chronic heart failure: interleukin‐8 is associated with adverse outcome. Results from CORONA , 2014, European journal of heart failure.

[21]  J. Zamorano,et al.  Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. , 2013, European heart journal cardiovascular Imaging.

[22]  A. Hayes.  Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach , 2013 .

[23]  K. Swedberg,et al.  Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. , 2013, European heart journal.

[24]  N. Uriel,et al.  Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome , 2012, Heart Failure Reviews.

[25]  M. Metra,et al.  Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure?: The Role of Congestion and Its Interaction With Renal Function , 2012, Circulation. Heart failure.

[26]  P. Steendijk,et al.  Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction , 2011, Circulation. Heart failure.

[27]  D. J. Veldhuisen,et al.  Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality , 2010, European journal of heart failure.

[28]  P. Ponikowski,et al.  Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine , 2010, European journal of heart failure.

[29]  G. Navis,et al.  Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. , 2009, Journal of the American College of Cardiology.

[30]  L. Tavazzi,et al.  Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  F. López-Ríos,et al.  Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure , 2005, European journal of heart failure.

[32]  B. Yawn,et al.  Trends in heart failure incidence and survival in a community-based population. , 2004, JAMA.

[33]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[34]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[35]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[36]  N. Freemantle,et al.  The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .

[37]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[38]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[39]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[40]  Josef Niebauer,et al.  Endotoxin and immune activation in chronic heart failure: a prospective cohort study , 1999, The Lancet.

[41]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[42]  D. Levy,et al.  The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.

[43]  C. Ronco,et al.  The role of inflammation in the cardio-renal syndrome: a focus on cytokines and inflammatory mediators. , 2012, Seminars in nephrology.

[44]  R. Bonow,et al.  Current medical therapy for advanced heart failure. , 2000, Heart & lung : the journal of critical care.